S-1: Aptevo Therapeutics Announces Public Offering of Common Stock and Warrants

Aptevo Therapeutics is launching a public offering to sell shares of common stock, pre-funded warrants, and common warrants, aiming to raise capital for clinical programs and general corporate purposes.

Summary

• Aptevo Therapeutics is undertaking a public offering of up to 13,513,513 shares of common stock along with common warrants to purchase up to 27,027,026 shares.
• Pre-funded warrants are also being offered as an alternative to common stock for purchasers who would exceed beneficial ownership limits of 4.99% or 9.99%.
• Each pre-funded warrant is exercisable for one share of common stock at $0.0001 per share.
• The offering includes two common warrants for each share of common stock or pre-funded warrant, exercisable upon stockholder approval at a price of $ per share, expiring five years from the approval date.
• Roth Capital Partners is acting as the exclusive placement agent, with Dawson James Securities, Inc. as co-agent.
• The offering is expected to terminate by October 15, 2024.
• The company intends to use the net proceeds, estimated at $4.4 million (excluding warrant exercises), for working capital and general corporate purposes, including the development of product candidates.

Sentiment

Score: 4

Explanation: The announcement is a mixed bag. While it provides necessary funding, it also carries risks of dilution and uncertainty regarding warrant exercisability. The company's financial situation necessitates this offering, indicating potential challenges.

Positives

• The offering provides capital to fund clinical programs and general corporate purposes.
• The pre-funded warrant option allows broader investor participation without exceeding ownership limits.
• The company has flexibility in allocating the net proceeds of the offering.

Negatives

• The offering may cause immediate and substantial dilution to new investors.
• There is no established public market for the common warrants or pre-funded warrants.
• The common warrants are not exercisable until Stockholder Approval and may not have any value.
• The offering is a reasonable best efforts offering, and there is no guarantee that the company will raise the amount of capital it believes is required for its business plans.

Risks

• The company has broad discretion in the use of the net proceeds from this offering and may not use them effectively.
• The price per share, together with the number of shares of common stock we propose to issue and ultimately will issue if this offering is completed, may result in an immediate decrease in the market price of our common stock.
• The common warrants are not exercisable until Stockholder Approval and may not have any value.
• The common warrants and pre-funded warrants are speculative in nature.
• This is a reasonable best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.
• Our common stock may be at risk for delisting from the Nasdaq Capital Market in the future if we do not maintain compliance with Nasdaqs continued listing requirements.

Future Outlook

The company intends to use the net proceeds from this offering for working capital to fund its clinical programs and general corporate purposes, including the further development of its product candidates.

Industry Context

Bispecific therapeutics are increasingly recognized as potent anti-cancer agents. Eleven new bispecific agents have been approved for use by the FDA in the last three years and there is a total of 125 bispecific drug candidates currently in development.

Stakeholder Impact

• Existing shareholders will experience dilution.
• New investors face the risk of price decrease and warrant value uncertainty.
• The company aims to secure funding for ongoing clinical programs, potentially benefiting patients in the long term.

Next Steps

• The company will seek stockholder approval to permit the exercise of the common warrants.
• The company will file a Prospectus Supplement with the Commission pursuant to Rule 424(b).
• The company will apply to list or quote all of the Shares and Warrant Shares on the Trading Market.

Key Dates

Keywords

public offering, common stock, pre-funded warrants, common warrants, Aptevo Therapeutics, capital raise, clinical programs, Roth Capital Partners, Dawson James Securities